NasdaqGS - Nasdaq Real Time Price USD
Seres Therapeutics, Inc. (MCRB)
7.50
+0.13
+(1.78%)
As of 11:02:42 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 2 | 2 |
| Avg. Estimate | -2.61 | -0.62 | 0.14 | -5.01 |
| Low Estimate | -3.27 | -2.8 | -1.61 | -7.59 |
| High Estimate | -1.95 | 1.21 | 1.88 | -2.43 |
| Year Ago EPS | -4.4 | -6.6 | -16.19 | 0.14 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -- | 5.88M | 5.88M | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | 23.5M | 23.5M | -- |
| Year Ago Sales | -- | -- | -- | 5.88M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | -100.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -5.91 | -0.04 | -3.99 | 1.97 |
| EPS Actual | -4.4 | -6.6 | -2.2 | -2.24 |
| Difference | 1.51 | -6.56 | 1.79 | -4.21 |
| Surprise % | 25.52% | -16,630.04% | 44.80% | -213.57% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -2.61 | -0.62 | 0.14 | -5.01 |
| 7 Days Ago | -1.83 | 0.08 | -1.12 | -1.47 |
| 30 Days Ago | -1.4 | 0.1 | -1.12 | -1.47 |
| 60 Days Ago | -1.4 | 0.1 | -2.38 | -2.23 |
| 90 Days Ago | -3.5 | -3.1 | -8.18 | -8.23 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| MCRB | 40.74% | 90.61% | 100.84% | -3,785.30% |
| S&P 500 | 13.17% | 3.05% | 8.05% | 13.75% |
Upgrades & Downgrades
| Downgrade | Chardan Capital: Buy to Neutral | 5/8/2025 |
| Maintains | Chardan Capital: Buy to Buy | 3/20/2025 |
| Maintains | Goldman Sachs: Sell to Sell | 3/14/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/14/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/13/2024 |
| Downgrade | JP Morgan: Neutral to Underweight | 10/24/2024 |
Related Tickers
CHRS Coherus BioSciences, Inc.
0.8011
-2.91%
DAWN Day One Biopharmaceuticals, Inc.
6.22
-1.82%
ACXP Acurx Pharmaceuticals, Inc.
0.3808
+0.24%
LXRX Lexicon Pharmaceuticals, Inc.
0.5601
-11.10%
AUPH Aurinia Pharmaceuticals Inc.
7.64
-2.37%
PDSB PDS Biotechnology Corporation
1.3109
+3.22%
KPTI Karyopharm Therapeutics Inc.
4.9017
-0.37%
XFOR X4 Pharmaceuticals, Inc.
3.2900
-0.60%
AXSM Axsome Therapeutics, Inc.
104.06
-1.52%
IOVA Iovance Biotherapeutics, Inc.
1.7106
-4.42%